Kiora Pharmaceuticals shares rise 11.11% intraday after closing $5M private placement with $19M warrant upside.

Kiora Pharmaceuticals surged 11.11% in intraday trading following the announcement that it closed a private placement raising up to $24 million. The transaction, led by Perceptive Advisors and ADAR1 Capital Management, secured $5 million in upfront proceeds with an additional $19 million in potential proceeds from warrant exercises. This capital infusion addresses the company's cash burn concerns and funds ongoing research and development for its retinal disease pipeline, including KIO-301 and KIO-104. The strategic financing, executed at the market price without a placement agent, was viewed positively by investors as a critical step in extending the clinical-stage biotech's operational runway.